IL232942B - A method for treating alveolar bone loss by using antibodies against sclerostin - Google Patents

A method for treating alveolar bone loss by using antibodies against sclerostin

Info

Publication number
IL232942B
IL232942B IL232942A IL23294214A IL232942B IL 232942 B IL232942 B IL 232942B IL 232942 A IL232942 A IL 232942A IL 23294214 A IL23294214 A IL 23294214A IL 232942 B IL232942 B IL 232942B
Authority
IL
Israel
Prior art keywords
bone loss
alveolar bone
sclerostin antibodies
treating alveolar
treating
Prior art date
Application number
IL232942A
Other languages
English (en)
Hebrew (he)
Other versions
IL232942A0 (en
Original Assignee
Amgen Inc
Univ Michigan Regents
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47429046&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL232942(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc, Univ Michigan Regents filed Critical Amgen Inc
Publication of IL232942A0 publication Critical patent/IL232942A0/en
Publication of IL232942B publication Critical patent/IL232942B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL232942A 2011-12-28 2014-06-02 A method for treating alveolar bone loss by using antibodies against sclerostin IL232942B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161580964P 2011-12-28 2011-12-28
PCT/US2012/068975 WO2013101451A1 (en) 2011-12-28 2012-12-11 Method of treating alvelor bone loss through the use of anti-sclerostin antibodies

Publications (2)

Publication Number Publication Date
IL232942A0 IL232942A0 (en) 2014-07-31
IL232942B true IL232942B (en) 2018-10-31

Family

ID=47429046

Family Applications (2)

Application Number Title Priority Date Filing Date
IL232942A IL232942B (en) 2011-12-28 2014-06-02 A method for treating alveolar bone loss by using antibodies against sclerostin
IL259939A IL259939B (en) 2011-12-28 2018-06-11 A method for treating alveolar bone loss by using antibodies against sclerostin

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL259939A IL259939B (en) 2011-12-28 2018-06-11 A method for treating alveolar bone loss by using antibodies against sclerostin

Country Status (19)

Country Link
US (3) US9657090B2 (forum.php)
EP (2) EP3712168A3 (forum.php)
JP (3) JP6363954B2 (forum.php)
KR (3) KR20190120401A (forum.php)
CN (2) CN104039828B (forum.php)
AR (1) AR089509A1 (forum.php)
AU (3) AU2012362898B2 (forum.php)
BR (1) BR112014016108A2 (forum.php)
CA (1) CA2858974A1 (forum.php)
CL (1) CL2014001719A1 (forum.php)
EA (2) EA036740B1 (forum.php)
ES (1) ES2813524T3 (forum.php)
IL (2) IL232942B (forum.php)
IN (1) IN2014CN04634A (forum.php)
MX (1) MX354270B (forum.php)
SG (2) SG11201403718YA (forum.php)
TW (3) TW201811364A (forum.php)
WO (1) WO2013101451A1 (forum.php)
ZA (1) ZA201404610B (forum.php)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
MX382826B (es) * 2010-10-27 2025-03-13 Amgen Inc Anticuerpos dkk1 y metodos de uso.
BR112013024493A2 (pt) 2011-03-25 2018-06-26 Amgen Inc. cristais de anticorpo antiesclerostina e formulações dos mesmos
MX354270B (es) * 2011-12-28 2018-02-21 Amgen Inc Uso de un anticuerpo antiesclerostina en el tratamiento de la pérdida ósea alveolar. .
CN105451660B (zh) * 2013-07-19 2020-08-21 Axion 日本株式会社 全景图像摄影装置及该装置中所使用的图像诊断方法
ES2835923T3 (es) * 2015-03-13 2021-06-23 Jiangsu Hengrui Medicine Co Anticuerpo antiesclerostina, fragmento de unión a antígeno y uso médico del mismo
JP2020502218A (ja) 2016-12-21 2020-01-23 メレオ バイオファーマ ３ リミテッド 骨形成不全症の処置における抗スクレロスチン抗体の使用
JP7120531B2 (ja) * 2018-02-12 2022-08-17 アプタキュア セラピューティクス リミテッド スクレロスチンに対するアプタマー及びその使用
US12229964B2 (en) * 2018-10-30 2025-02-18 Diagnocat Inc. Probabilistic segmentation of volumetric images
US12062170B2 (en) * 2018-10-30 2024-08-13 Diagnocat Inc System and method for classifying a tooth condition based on landmarked anthropomorphic measurements
WO2021191903A1 (en) * 2020-03-26 2021-09-30 Bone Sci. Bio Ltd. Pharmaceutical compositions comprising amphiphilic peptides and methods of use thereof
KR102472582B1 (ko) * 2020-08-20 2022-11-30 한림대학교 산학협력단 인공관절 마모편에 의한 활막염과 골용해의 진단 및 치료 방법
IL301763A (en) * 2020-09-28 2023-05-01 Angitia Biomedicines Ltd Anti-sclerostin constructs and uses thereof

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
US4427115A (en) 1981-10-19 1984-01-24 Laipply Thomas C One piece alcohol preparation device
USRE32011E (en) 1981-12-14 1985-10-22 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
US4543439A (en) 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
JPH0647532B2 (ja) * 1983-08-31 1994-06-22 ジ アツプジヨン カンパニ− 歯槽骨吸収の治療
US6054561A (en) 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
DE3417525C1 (de) 1984-05-11 1986-01-09 Matter + Siegmann Ag, Wohlen Vorrichtung zur quantitativen und qualitativen Erfassung von kohlenwasserstoffhaltigen Schwebeteilchen in Gasen
US4902614A (en) 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5177197A (en) 1990-02-27 1993-01-05 Ludwig Institute For Cancer Research Isolated nucleotide sequence expressing human transforming growth factor-β1-binding protein
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
JPH04141095A (ja) 1990-10-02 1992-05-14 Chemo Sero Therapeut Res Inst 組換え抗ｈｉｖ改変抗体および改変抗体の調製方法
US5070108A (en) 1990-10-12 1991-12-03 Trustees Of The University Of Pennsylvania Methods of treating osteoporosis, increasing bone mineral content and preventing the occurrence of compression fractures in a mammal
WO1992006693A1 (en) 1990-10-22 1992-04-30 Fox Chase Cancer Center Dna construct for providing rna therapy
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
EP0628639B1 (en) 1991-04-25 1999-06-23 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
AU700371B2 (en) 1993-06-07 1999-01-07 Genentech Inc. Hiv envelope polypeptides
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5453492A (en) 1993-07-28 1995-09-26 La Jolla Cancer Research Foundation 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
ATE378407T1 (de) 1994-04-29 2007-11-15 Curis Inc Morphogene protein-spezifische zelloberflächenrezeptoren und ihre verwendungen
DE4427221A1 (de) 1994-08-01 1996-02-08 Gsf Forschungszentrum Umwelt Retrovirus-induzierte Osteoklasten-Modulation für die Osteoporose-Therapie
US5846770A (en) 1994-11-22 1998-12-08 Genetics Institute, Inc. DNA molecules encoding human chordin
US6057421A (en) 1994-11-30 2000-05-02 Immpheron, Inc. Variable heavy and light chain regions of murine monoclonal antibody 1F7
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
EP0871705A4 (en) 1995-06-05 2000-01-26 Human Genome Sciences Inc CCN TYPE HUMAN GROWTH FACTOR
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
AU725238B2 (en) 1996-05-22 2000-10-12 Viventia Biotech Inc. Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
WO2000075317A2 (en) 1999-06-09 2000-12-14 Genentech, Inc. Compositions and methods for the treatment of tumor
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US5989909A (en) 1997-09-26 1999-11-23 Millennium Biotherapeutics, Inc. Huchordin and uses thereof
WO1998046588A2 (en) 1997-04-11 1998-10-22 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
ES2301198T3 (es) 1997-06-12 2008-06-16 Novartis International Pharmaceutical Ltd. Polipeptidos artificiales de anticuerpos.
US6075007A (en) 1997-07-17 2000-06-13 Regeneron Pharmaceuticals, Inc. Modified noggin polypeptide and compositions
CA2297109A1 (en) 1997-08-01 1999-02-11 Genset 5' ests for secreted proteins expressed in muscle and other mesodermal tissues
US6815201B2 (en) 1997-09-08 2004-11-09 The Public Health Research Institute Of The City Of New York, Inc. HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies
AU4595399A (en) 1998-06-19 2000-01-10 Mcgill University Antisense oligonucleotide constructs based on beta-arabinofuranose and its analogues
US6544485B1 (en) 2001-01-29 2003-04-08 Sharper Image Corporation Electro-kinetic device with enhanced anti-microorganism capability
ES2639020T3 (es) 1998-11-27 2017-10-25 Ucb Pharma S.A. Composiciones y métodos para incrementar la mineralización de la substancia ósea
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
AU3475100A (en) 1999-01-29 2000-08-18 Imclone Systems Incorporated Antibodies specific to kdr and uses thereof
JP2003525611A (ja) 2000-03-02 2003-09-02 アムジェン インコーポレーテッド コルディン様−２分子およびその使用
CA2410912A1 (en) 2000-06-01 2001-12-06 Amgen, Inc. Cystine-knot polypeptides: cloaked-2 molecules and uses thereof
AU2001272482A1 (en) 2000-06-19 2002-01-02 F.Hoffmann-La Roche Ag Osteolevin gene polymorphisms
JP4451059B2 (ja) 2000-09-01 2010-04-14 ジェネンテック インコーポレイテッド 分泌及び膜貫通ポリペプチドとそれをコードする核酸
EP1324776B2 (en) 2000-10-12 2018-03-21 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
CA2374027A1 (en) 2001-03-13 2002-09-13 The Minister Of National Defence Cloning, expression, sequencing, and functional enhancement of monoclonal scfv antibody against venezuelan equine encephalitis virus(vee)
DE10145772A1 (de) 2001-09-17 2003-04-10 Bayer Cropscience Ag DELTA·1·-Pyrroline
ES2660641T3 (es) 2001-12-06 2018-03-23 Biocontrol Systems, Inc. Sistema de recogida y de ensayo de muestras
US20030186915A1 (en) 2002-02-11 2003-10-02 Yang Pan Regulatory polynucleotides and uses thereof
EP1575481A4 (en) 2002-03-01 2010-01-06 Celltech R & D Inc PROCESS FOR INCREASING OR REDUCING THE BONE DENSITY
WO2003087763A2 (en) 2002-04-03 2003-10-23 Celltech R & D, Inc. Association of polymorphisms in the sost gene region with bone mineral density
AU2003276430A1 (en) 2002-06-14 2003-12-31 Stowers Institute For Medical Research Wise/sost nucleic acid sequences and amino acid sequences
US7893218B2 (en) 2003-06-16 2011-02-22 Stowers Institute For Medical Research Antibodies that specifically bind SOST peptides
EP1572122A4 (en) 2002-11-01 2008-04-09 Us Gov Health & Human Serv METHOD FOR PREVENTING INFECTIONS OF BIOTERRORISM AGENTS WITH IMMUNOSTIMULATING CPG OLIGONUCLEOTIDES
US7642238B2 (en) 2002-12-05 2010-01-05 Shaughnessy John D Molecular determinants of myeloma bone disease and uses thereof
CN1732023A (zh) * 2002-12-27 2006-02-08 血管技术国际股份公司 组合物和使用collajolie的方法
US20040141875A1 (en) 2003-01-15 2004-07-22 Rajiv Doshi System and method for treating microorganisms within motor vehicle heating, ventilation, and air conditioning units
US20050281756A1 (en) * 2004-06-14 2005-12-22 Eamonn Connolly Use of lactic acid bacteria for decreasing gum bleeding and reducing oral inflammation
GB0304030D0 (en) 2003-02-21 2003-03-26 King S College London Teeth
PT1608399E (pt) 2003-03-14 2012-04-13 Ucb Mfg Inc Complexo de esclerostina e noguina ou cordina, e agentes que modulam a formação do referido complexo
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
CU23403A1 (es) 2003-04-23 2009-08-04 Centro Inmunologia Molecular Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
RS20050934A (en) 2003-06-16 2008-04-04 Celltech R. & D. Inc., Antibodies specific for sclerostin and methods fo r increasing bone mineralization
US8461155B2 (en) 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
GB0324854D0 (en) 2003-10-24 2003-11-26 Expresson Biosystems Ltd App/ena antisense
US20050267233A1 (en) 2004-05-25 2005-12-01 Joshi Ashok V Anti-microbial handle system
JP4840939B2 (ja) 2004-08-04 2011-12-21 アムジェン インコーポレイテッド Ｄｋｋ−１に対する抗体
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8541177B2 (en) 2006-01-13 2013-09-24 A Chan Holding B.V. Treatment and diagnosis of abnormal bone density with an inhibitor of the glypican-sclerostin interaction
EP2423226A3 (en) 2006-11-10 2012-05-30 Amgen Inc. Antibody-based diagnostics and therapeutics
WO2008133722A2 (en) 2006-11-10 2008-11-06 Ucb Pharma S.A. Anti human sclerostin antibodies
JP2010528002A (ja) 2006-12-29 2010-08-19 オステオジェネックス インコーポレイテッド Ｓｏｓｔもしくはｗｉｓｅアンタゴニストまたはアゴニストの投与による骨成長を変化させる方法
US20100028335A1 (en) 2007-02-02 2010-02-04 Novartis Ag Compositions and Methods to Treat Bone Related Disorders
MX2009010051A (es) * 2007-03-20 2009-10-12 Lilly Co Eli Anticuerpos anti-esclereostina.
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
AR068767A1 (es) 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
EA201000718A1 (ru) 2007-11-02 2011-06-30 Новартис Аг Молекулы и способы, предназначенные для модуляции родственного рецептору липопротеидов низкой плотности белка 6 (lrp6)
EP2628486A3 (en) * 2007-12-14 2013-10-30 Amgen, Inc. Method for treating bone fracture with anti-sclerostin antibodies
AR072001A1 (es) 2008-06-03 2010-07-28 Abbott Lab Inmunoglobulina con dominio variable dual y usos de la misma
EP2311200B1 (fr) 2008-06-30 2020-06-03 3G Licensing S.A. Communications cooperatives multicellulaires dans un reseau decentralisé
GB0903689D0 (en) 2009-03-03 2009-04-15 Sigmavision Ltd Vehicle tyre measurement
WO2010100179A2 (en) * 2009-03-05 2010-09-10 Novartis Ag Self-forming gel system for sustained drug delivery
AR075715A1 (es) 2009-03-05 2011-04-20 Novartis Ag Formulacion de anticuerpo liofilizado
WO2010115932A1 (en) 2009-04-08 2010-10-14 Novartis Ag Combination for the treatment of bone loss
WO2010130830A2 (en) 2009-05-15 2010-11-18 Ablynx N.V. Amino acid sequences directed against sclerostin and polypeptides comprising the same for the treatment of bone diseases and disorders
MX2012012050A (es) * 2010-04-16 2012-11-22 Novartis Ag Metodos y composiciones para mejorar la oseointegracion de implantes.
SMT202000095T1 (it) * 2010-05-14 2020-03-13 Amgen Inc Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery
MX382826B (es) 2010-10-27 2025-03-13 Amgen Inc Anticuerpos dkk1 y metodos de uso.
MX354270B (es) * 2011-12-28 2018-02-21 Amgen Inc Uso de un anticuerpo antiesclerostina en el tratamiento de la pérdida ósea alveolar. .

Also Published As

Publication number Publication date
EA036740B1 (ru) 2020-12-15
MX2014007965A (es) 2014-11-25
TW201811364A (zh) 2018-04-01
JP2019031567A (ja) 2019-02-28
MX354270B (es) 2018-02-21
EP2797953B1 (en) 2020-06-03
IL259939B (en) 2020-05-31
CN104039828B (zh) 2017-07-21
ES2813524T3 (es) 2021-03-24
TWI706787B (zh) 2020-10-11
TW202114733A (zh) 2021-04-16
HK1198367A1 (zh) 2015-04-10
EP3712168A3 (en) 2020-10-14
KR20190120401A (ko) 2019-10-23
JP2015504887A (ja) 2015-02-16
IL259939A (en) 2018-07-31
SG11201403718YA (en) 2014-07-30
WO2013101451A8 (en) 2014-06-26
US20170281761A1 (en) 2017-10-05
CA2858974A1 (en) 2013-07-04
US20180169234A1 (en) 2018-06-21
TW201330859A (zh) 2013-08-01
JP6363954B2 (ja) 2018-07-25
US9913900B2 (en) 2018-03-13
EP2797953A1 (en) 2014-11-05
BR112014016108A2 (pt) 2018-09-11
EA202091676A1 (ru) 2021-01-29
SG10201509629QA (en) 2015-12-30
KR20140116089A (ko) 2014-10-01
AU2018200649A1 (en) 2018-02-15
JP2017214359A (ja) 2017-12-07
IN2014CN04634A (forum.php) 2015-09-18
AR089509A1 (es) 2014-08-27
KR102033669B1 (ko) 2019-10-18
KR20200056473A (ko) 2020-05-22
US20140314776A1 (en) 2014-10-23
CN107126560A (zh) 2017-09-05
CL2014001719A1 (es) 2014-11-03
AU2019275548A1 (en) 2020-01-02
AU2012362898B2 (en) 2017-11-09
WO2013101451A1 (en) 2013-07-04
EA201491286A1 (ru) 2014-09-30
ZA201404610B (en) 2017-11-29
US9657090B2 (en) 2017-05-23
AU2012362898A1 (en) 2014-07-24
CN104039828A (zh) 2014-09-10
IL232942A0 (en) 2014-07-31
EP3712168A2 (en) 2020-09-23

Similar Documents

Publication Publication Date Title
IL259939B (en) A method for treating alveolar bone loss by using antibodies against sclerostin
IL229582A0 (en) Antibodies against kir for the treatment of inflammatory disorders
GB201110095D0 (en) Method of treatment
EP2773754A4 (en) Methods of Treatment
ZA201305972B (en) Method for the preparation of biphephos
PL3026064T3 (pl) Przeciwciała do leczenia nowotworu z ekspresją klaudyny 6
PT2489670T (pt) Processo para a preparação de compostos de quelatos de aminoácidos, compostos de quelatos de aminoácidos e utilização de compostos de quelatos de aminoácidos
ZA201208172B (en) Methods for the treatment of il-1b related conditions
SG10201505454SA (en) Methods and compositions for treating asthma using anti-il-13 antibodies
IL232190A0 (en) A method for treating inflammatory diseases by anti-m-csf antibodies
EP2758780A4 (en) METHOD OF TREATING MULTIPLE SCLEROSIS
SG11201400405TA (en) Caninised antibodies and method for the production of same
PH12013501838A1 (en) Cement composition and method for producing the same
PT2757878E (pt) Método para a preparação e aperfeiçoamento de ferraduras
PL2691103T3 (pl) Metoda leczenia zaburzeń skóry
LT2785879T (lt) Biologinis listerijų kontrolės būdas
HUE038149T2 (hu) Eljárás acél kezelésére
GB201020045D0 (en) Method for the treatment of biogas
GB201105523D0 (en) Treatment method
ZA201400716B (en) A method for the treatment of hair
EP2791324A4 (en) PROCESSING METHOD
GB201111530D0 (en) Method of treatment
GB201109509D0 (en) Method of treatment
GB201109266D0 (en) Method of treatment
GB201103044D0 (en) Method of treatment

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed